Gabriel Mashabela

Dr. Gabriel Mashabela

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2019 in Microbiology Spectrum
Verified
Journal Article
Closed access
GMGabriel Mashabela
Gabriel Mashabela
TWTimothy J. de Wet
Timothy J. de Wet
DWDigby Warner
Digby Warner
Mycobacterium tuberculosis is the cause of tuberculosis (TB), a disease which continues to overwhelm health systems in endemic regions despite the existence of effective combination chemotherapy and the widespread use of a neonatal anti-TB vaccine. For a professional pathogen, M. tuberculosis retains a surprisingly large proportion of the metabolic repertoire found in nonpathogenic mycobacteria with very different lifestyles. Moreover, evidence that additional functions were acquired during the early evolution of the M. tuberculosis complex suggests the organism has adapted (and augmented) the metabolic pathways of its environmental ancestor to persistence and propagation within its obligate human host. A better understanding of M. tuberculosis pathogenicity, however, requires the elucidation of metabolic functions under disease-relevant conditions, a challenge complicated by limited knowledge of the microenvironments occupied and nutrients accessed by bacilli during host infection, as well as the reliance in experimental mycobacteriology on a restricted number of experimental models with variable relevance to clinical disease. Here, we consider M. tuberculosis metabolism within the framework of an intimate host-pathogen coevolution. Focusing on recent advances in our understanding of mycobacterial metabolic function, we highlight unusual adaptations or departures from the better-characterized model intracellular pathogens. We also discuss the impact of these mycobacterial “innovations” on the susceptibility of M. tuberculosis to existing and experimental anti-TB drugs, as well as strategies for targeting metabolic pathways. Finally, we offer some perspectives on the key gaps in the current knowledge of fundamental mycobacterial metabolism and the lessons which might be learned from other systems.

16 June 2015 in ChemBioChem
Verified
Journal Article
Closed access
PDF file
AVAllegra Vit
Allegra Vit
GMGabriel Mashabela
Gabriel Mashabela
WBWulf Blankenfeldt
Wulf Blankenfeldt
FSFl Seebeck
Fl Seebeck

4 July 2013 in Chemical Communications
Verified
Journal Article
Open access
PDF file
GMGabriel Mashabela
Gabriel Mashabela
FSFl Seebeck
Fl Seebeck
OvoA is an iron(II) dependent sulfoxide synthase which catalyzes the first step in ovothiol A biosynthesis. This enzyme sulphurizes the C5 position of the imidazole side chain of L-histidine. We report the substrate specificity profile of this catalyst and present data which indicate that OvoA catalysis follows an thiol-ene type mechanism.

16 May 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
RMRamokone Florah Mothupi
Ramokone Florah Mothupi
MMMashilo Mash Matotoka
Mashilo Mash Matotoka
GMGabriel Mashabela
Gabriel Mashabela
PMPeter Masoko
Peter Masoko
The persistence of Mycobacterium tuberculosis within biofilm-like structures underscores the need for alternative drug discovery strategies aimed at resistance mechanisms. Medicinal plants provide a rich source of chemically diverse compounds with broad biological activities, including potential antimycobacterial properties. This study investigated acetone stem extracts from Buddleja saligna, Combretum hereroense, and Olea europaea subsp. africana for their phytochemical composition, antioxidant capacity, and antimycobacterial activity against planktonic and biofilm forms of Mycobacterium smegmatis. Phytochemical profiles were analyzed using liquid chromatography–mass spectrometry and quantified through colorimetric assays. Antioxidant activity was assessed using DPPH radical scavenging and ferric reducing power assays, while antimycobacterial effects at MIC and sub-MIC levels were determined through microdilution and growth kinetic assays. Phytochemical composition and concentrations varied among extracts, with B. saligna exhibiting the highest levels of tannins (287.18 ± 0.19 mgGAE/g extract) and flavonoids (16.48 ± 0.05 mgQE/g extract) and showing the strongest antioxidant activity (17.66 ± 5.396 and 399.1 ± 3.717 µg/mL). C. hereroense had a notable antimycobacterial activity with an MIC of 0.16 mg/mL followed by B. saligna and O. europaea subsp. afriana with MIC values of 0.31 and 0.63 mg/mL, respectively. All extracts significantly inhibited early biofilm formation by over 80% at sub-MICs. However, the mature biofilms and sliding motility were less susceptible to the extracts. Overall, the results confirm the antioxidant and antimycobacterial potential of the selected plant extracts, while highlighting challenges in targeting mycobacterial biofilms.

1 February 2026 in Antibiotics
Verified
Journal Article
Open access
PDF file
NMNenekazi Masikantsi
Nenekazi Masikantsi
RMRendani Mbau
Rendani Mbau
Nuhu Ibrahim TukurNuhu Ibrahim Tukur
Nuhu Ibrahim Tukur
PMPeter Masoko
Peter Masoko
GMGabriel Mashabela
Gabriel Mashabela
Background/Objectives: The increase in incidences of multidrug resistance exacerbates tuberculosis-related global health challenges and underscores a call for more efforts for development of new antitubercular drugs, including the use of medicinal plants, especially those that have been used for generations by traditional healers. Despite reports of antimicrobial activity and chemical profiling of Kirkia wilmsii (K. wilmsii) extracts, chemical structures of the bioactive agents have not been elucidated. Here, we used a combination of bioactivity-guided fractionation, mass spectrometry, and nuclear magnetic resonance to purify and elucidate the chemical structure of antimycobacterial agents contained in leaf and twig extracts for K. wilmsii. Results: After overnight extraction with acetone and 90 g of dry twigs and leaves produced 5.38 g (6%) and 4.56 g (5%) of product, which displayed moderate antimycobacterial activity of 0.5 and 1 mg/mL, respectively. The antimycobacterial activity was increased six- and three-fold, respectively, after the crude extracts were subjected to solvent–solvent partitioning. Due to many bioactive fractions being obtained after silica gel chromatography purification, fraction 5 of twig extract was prioritized for further purification due to its low minimum inhibitory concentration (MIC) (0.25 mg/mL) and cytotoxicity (20%, in THP-1 cells). Sequential purification of the fraction 5 (twig extract) extracts through the C18 cartridge and high-performance liquid chromatography (HPLC) produced four fractions, which were subjected to structural elucidation. The high-resolution mass spectrometric analyses revealed that the first two eluting peaks had the same mass ion of 441.0822 m/z (M − H−), which corresponded to catechin monogallate, and so were the last two eluting peaks, which had a mass ion of 539.0932 m/z (M − H−), corresponding to catechin digallate. Further analyses by 1H, 13C, and 2D NMR confirmed the chemical structures of compounds eluting in the first two peaks on HPLC as structural isomers of catechin 3′-monogallate and catechin 4′-monogallate (MIC not determined). Similarly, compounds eluting in the last two peaks were identified as structural isomers catechin 3′-digallate and catechin 4′-digallate, with an MIC of 250 µg/mL against Mycobacterium smegmatis and Mycobacterium tuberculosis H37Rv and an MBC of 500 μg/mL against M. smegmatis. Conclusions: To the best of our knowledge, this study is the first to report the structure of catechin 3′- and 4′-digallate, their antimycobacterial activity, and the existence of acyl migration involving galloyl 3′ and 4′-hydroxyl groups of catechin ring B.

4 November 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
TMTumelo Maila
Tumelo Maila
MNMischke Nicolaai
Mischke Nicolaai
RMRendani D Mbau
Rendani D Mbau
GMGabriel Mashabela
Gabriel Mashabela
A rapid emergence in the incidences of Tuberculosis (TB) drug resistance undermines efforts to eradicate the disease and strengthens calls for development of new drugs with novel mechanisms of action. In drug discovery, finding an attractive drug target is as important as finding a good drug candidate. Hence more efforts are made to identify, validate and prioritize drug targets in TB drug discovery. Here, using CRISPRi technology, we showed that dxs1 transcriptional knockdown attenuated growth of both Mycobacterium smegmatis and Mycobacterium tuberculosis cultures, and the effect was more profound in the latter. Chemical supplementation of the growth medium with 10 μM of isoprenoid pyrophosphates, thiamine and thiamine pyrophosphate failed to rescue growth of M. smegmatis cultures, while partial rescue was observed with addition of menatetrenone, a menaquinone derivative with four isoprenyl groups. Similarly, culture growth could not be rescued by the addition of prenol and isoprenol, which suggested the lack of isoprenoid salvage pathway in mycobacteria. Importantly, and in the context of drug discovery, dxs1 depleted mutants displayed four-fold more sensitive towards a mixture of isoniazid, rifampicin and ethambutol, suggesting that inhibitors of DXS enzyme or other MEP pathway enzymes could potentiate antimycobacterial effect of the first-line TB drugs. Additionally, dxs1 depletion increased growth retardation of the mutant in acidic pH and under oxidative stress, conditions that are encountered in activated macrophage compartments. Taken together, our results validated DXS as an attractive drug target that should be prioritized for developments on new antitubercular agents.